Imagine a world where a simple medication could save thousands of lives each year. Sounds too good to be true, right? But here’s where it gets groundbreaking: a new study suggests that a diabetes drug, already in use, could do just that. Researchers from the London School of Hygiene & Tropical Medicine (LSHTM) and UCL have uncovered compelling evidence that SGLT-2 inhibitors, when prescribed more widely, could dramatically reduce premature deaths among people with type 2 diabetes.
And this is the part most people miss: while clinical trials have long shown these drugs protect the heart and kidneys, they’ve only been tested on narrowly defined groups. What about the millions of real-world patients who don’t fit those criteria? This is where the new study, published in BMJ Open Diabetes Research & Care, steps in. By analyzing anonymized health records of over 60,000 people in the UK, researchers found that for every 47 individuals prescribed an SGLT-2 inhibitor, one life was saved over three years. With an estimated three million people in the UK living with type 2 diabetes, this could translate to 20,000 lives saved annually—a staggering figure.
Here’s how it works: SGLT-2 inhibitors lower blood sugar levels and have been proven to reduce the risk of cardiac events like strokes and heart attacks. But the real innovation here is the use of electronic health records to bridge the gap between controlled trials and real-world outcomes. The study employed a 'trial emulation' approach, mimicking clinical trial principles to avoid biases often found in big data analysis. This method revealed that patients on SGLT-2 inhibitors were 24% less likely to die prematurely compared to those on alternative medications.
But here’s where it gets controversial: while NICE (the UK’s health guidelines body) has proposed SGLT-2 inhibitors as a first-line treatment alongside metformin, this shift could spark debate. Currently, these drugs are only recommended for patients with additional risk factors like cardiovascular disease. Expanding their use to all type 2 diabetes patients would be a major policy change, affecting millions. Is this a step too far, or a necessary evolution in diabetes care? We’d love to hear your thoughts in the comments.
Dr. Patrick Bidulka, senior author of the study, emphasizes the power of patient data in shaping healthcare: 'This study shows how electronic health records can safely complement clinical trials, improving outcomes for patients.' Meanwhile, lead author Dr. David Ryan highlights the drug’s broader applicability: 'Our findings support NICE’s draft guidance, which could mean longer, healthier lives for millions of people with type 2 diabetes.'
As we await NICE’s final guidance in February 2026, one thing is clear: this research isn’t just about numbers—it’s about transforming lives. But the question remains: Are we ready to embrace this change, or is there more to consider? Let us know what you think.
.png?itok=vG4vqFkm)
